Study of Maintenance DCVACOvCa Therapy After First-line Chemotherapy in Women With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

What this Trial Is About

Researchers are evaluating the safety and effectiveness of maintenance DCVACOvCa therapy after first-line chemotherapy combined with standard care in women newly diagnosed with advanced FIGO stage III or IV ovarian, fallopian tube, or primary peritoneal carcinoma. This randomized, double-blind, placebo-controlled Phase 2 study aims to verify preliminary results for this approach in treating these cancers. The study compares two groups one receiving DCVACOvCa, an active cellular immunotherapy made from a patients own immune cells and tumor cells, and another receiving a placebo. Both treatments follow first-line chemotherapy and standard care. Participants are randomly assigned to either group and neither the participants nor researchers know who receives which treatment during the study. Participants will be monitored from randomization with follow-up for about two years to assess progression-free survival, measuring the time until disease progression or death. The study includes various assessments such as medical exams, laboratory tests, and safety monitoring. Participants must meet detailed eligibility criteria and will be followed closely to evaluate treatment effects and safety throughout the study period.

A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care